Paul Hastings Acquires Shares of enGene Therapeutics

Paul Hastings, a notable figure in the biotechnology sector, recently bought 31,000 shares of enGene Therapeutics Inc. (NasdaqCM:ENGN) on June 16, 2026. This transaction was not part of a pre-planned trading program, suggesting a personal vote of confidence in the company’s prospects.

enGene Therapeutics Stock Snapshot

Shares of enGene Therapeutics Inc. are currently trading around $1.75. The company, which operates in the biotechnology sector, has a market capitalization of about $117.2 million. It has a 52-week trading range between $1.40 and $12.25, indicating some volatility. The firm's 50-day moving average is $4.33, while the 200-day moving average stands at $7.13. enGene Therapeutics maintains a strong liquidity position with a current ratio of 12.57 and a quick ratio of 12.07, though it has a debt-to-equity ratio of 13.07.

About enGene Therapeutics

enGene Therapeutics Inc., based in Montreal, Canada, is a clinical-stage biotechnology company focused on developing genetic medicines. The company’s main product candidate, detalimogene voraplasmid, is a monotherapy aimed at treating non-muscle invasive bladder cancer (NMIBC). enGene also has other projects in its pipeline, including the LEGEND program, which is currently in Phase 2 trials. Under the leadership of CEO Ronald H. W. Cooper, the company employs 81 people.

Bottom Line

Paul Hastings' acquisition of enGene Therapeutics shares is a noteworthy insider move that might reflect confidence in the company’s future. While 13F filings and insider transactions provide valuable insights into investor sentiment, they are backward-looking and may not represent the current position. Investors often track these activities to gauge insider perspectives on company performance and potential growth.